A Phase II trial of MEK inhibitor BAY 86-9766 in combination with sorafenib as first-line systemic treatment for patients with unresectable hepatocellular carcinoma
Refereed conference paper presented and published in conference proceedings


Full Text

Other information
All Author(s) ListLIM H Y, YEN C J, TAK W Y, HEO J, CHOI H J, LIN C Y, YOON J H, HSU C, RAU K M, POON R, YEO Winnie, PARK J W, TAY M H, HSIEH W S, KAPPELER C, RAJAGOPALAN P, KRISSEL H
Name of ConferenceAnnual Meeting of the American Society of Clinical Oncology
Start Date of Conference01/06/2012
Country/Region of ConferenceUnited States of America
Proceedings TitleAnnual Meeting of the American Society of Clinical Oncology
Year2012
Month6
Place of PublicationUnited States of America
Pages1
LanguagesEnglish-United Kingdom
KeywordsHepaatocellular Carcinoma

Last updated on 2018-19-01 at 18:21